The involvement of PPARγ agonism in exacerbating hepatic steatosis and liver damage triggered by BBR in db/db mice was confirmed using a pharmacologically targeted strategy involving the administration of GW9662, a selective PPARγ antagonist (Figure7A). Here, PPARG is linked to fatty liver disease.